PL1605971T3 - Kompozycja immunogenna i sposoby - Google Patents

Kompozycja immunogenna i sposoby

Info

Publication number: PL1605971T3
Authority: PL; Poland
Prior art keywords: mammalian; subject; rvsv; composition; effective amount
Prior art date: 2003-03-26

Application number

PL04722764T

Other languages

English (en)

Inventor

John H Eldridge

Zimra R Israel

Michael A Egan

Stephen A Udem

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-26

Filing date

2004-03-23

Publication date

2010-10-29

2004-03-23 Application filed by Wyeth Llc filed Critical Wyeth Llc

2010-10-29 Publication of PL1605971T3 publication Critical patent/PL1605971T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Tropical Medicine & Parasitology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL04722764T 2003-03-26 2004-03-23 Kompozycja immunogenna i sposoby PL1605971T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US45787603P	2003-03-26	2003-03-26
US54673304P	2004-02-23	2004-02-23
PCT/US2004/006089 WO2004093906A1 (en)	2003-03-26	2004-03-23	Immunogenic composition and methods
EP04722764A EP1605971B1 (en)	2003-03-26	2004-03-23	Immunogenic composition and methods

Publications (1)

Publication Number	Publication Date
PL1605971T3 true PL1605971T3 (pl)	2010-10-29

Family

ID=42828775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04722764T PL1605971T3 (pl)	2003-03-26	2004-03-23	Kompozycja immunogenna i sposoby

Country Status (13)

Country	Link
US (2)	US20070134200A1 (pl)
EP (1)	EP1605971B1 (pl)
JP (1)	JP2006523224A (pl)
CN (1)	CN1764474B (pl)
AT (1)	ATE468859T1 (pl)
AU (1)	AU2004231464B2 (pl)
BR (1)	BRPI0408779A (pl)
CA (1)	CA2517010C (pl)
DK (1)	DK1605971T3 (pl)
MX (1)	MXPA05008526A (pl)
NZ (1)	NZ542652A (pl)
PL (1)	PL1605971T3 (pl)
WO (1)	WO2004093906A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6861422B2 (en)	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ES2345198T3 (es) *	2003-03-26	2010-09-17	Wyeth Llc	Composicion y procedimientos inmunologicos.
TW200613554A (en) *	2004-06-17	2006-05-01	Wyeth Corp	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
DE102004029784A1 (de)	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de)	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en)	2004-08-14	2010-06-01	Boehringer Ingelheim International Gmbh	Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en)	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en)	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060074088A1 (en)	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de)	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de)	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
WO2006110344A1 (en) *	2005-04-07	2006-10-19	Wyeth	Novel methods for inducing an immune response against human immunodefiency virus
US7439358B2 (en)	2006-02-08	2008-10-21	Boehringer Ingelheim International Gmbh	Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2185559A1 (en)	2007-08-03	2010-05-19	Boehringer Ingelheim International GmbH	Crystalline form of a dihydropteridione derivative
KR101723900B1 (ko) *	2009-06-08	2017-04-07	더 유니버시티 오브 웨스트 온타리오	면역화 요법용 발현 벡터로서의 수포성 구내염 바이러스의 상이한 혈청형
CN102803502B (zh) *	2009-09-29	2019-06-04	宾夕法尼亚大学理事会	用于诊断和治疗脑炎或癫痫的方法
US8546566B2 (en)	2010-10-12	2013-10-01	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
SI2654785T1 (sl) *	2010-12-22	2019-06-28	Bayer Intellectual Property Gmbh	Ojačan imunski odziv pri govejih vrstah
US9370535B2 (en)	2011-05-17	2016-06-21	Boehringer Ingelheim International Gmbh	Method for treatment of advanced solid tumors
JP2016525532A (ja)	2013-07-26	2016-08-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	骨髄異形成症候群の処置
CA2940794C (en)	2014-02-28	2022-05-31	Bayer Animal Health Gmbh	Immunostimulatory plasmids
AU2015225553B2 (en) *	2014-03-01	2020-02-27	Profectus Biosciences, Inc.	Recombinant Isfahan viral vectors
US9867831B2 (en)	2014-10-01	2018-01-16	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
TW201718001A (zh)	2015-07-31	2017-06-01	拜耳動物保健有限公司	豬物種中增強之免疫反應
CN105567646B (zh) *	2016-02-22	2019-01-01	浙江大学	分泌抗甘蔗花叶病毒单抗杂交瘤细胞株及其单抗应用
CN113968907B (zh) *	2020-07-22	2023-05-26	中国人民解放军军事科学院军事医学研究院	具有中和活性的抗尼帕病毒单克隆抗体及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU44186B (en) *	1978-12-22	1990-04-30	Biogen Nv	Process for obtaining recombinant dnk molecules
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5593972A (en) *	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
US7153510B1 (en) *	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
US20040013684A1 (en) *	2000-04-27	2004-01-22	Benjamin Rovinski	Immunizing against hiv infection
US20030021805A1 (en) *	2001-05-29	2003-01-30	Barber Glen N.	Generation of HCV-like particles and chimeric HCV virus
CA2452517A1 (en) *	2001-07-11	2003-01-23	University Of Miami	Recombinant vsv for the treatment of tumor cells

2004
- 2004-03-23 AT AT04722764T patent/ATE468859T1/de active
- 2004-03-23 CN CN2004800078180A patent/CN1764474B/zh not_active Expired - Lifetime
- 2004-03-23 MX MXPA05008526A patent/MXPA05008526A/es active IP Right Grant
- 2004-03-23 NZ NZ542652A patent/NZ542652A/en unknown
- 2004-03-23 BR BRPI0408779-8A patent/BRPI0408779A/pt not_active Application Discontinuation
- 2004-03-23 JP JP2006508920A patent/JP2006523224A/ja not_active Withdrawn
- 2004-03-23 CA CA2517010A patent/CA2517010C/en not_active Expired - Lifetime
- 2004-03-23 US US10/550,313 patent/US20070134200A1/en not_active Abandoned
- 2004-03-23 AU AU2004231464A patent/AU2004231464B2/en not_active Expired
- 2004-03-23 PL PL04722764T patent/PL1605971T3/pl unknown
- 2004-03-23 WO PCT/US2004/006089 patent/WO2004093906A1/en not_active Ceased
- 2004-03-23 DK DK04722764.0T patent/DK1605971T3/da active
- 2004-03-23 EP EP04722764A patent/EP1605971B1/en not_active Expired - Lifetime
2012
- 2012-04-24 US US13/454,884 patent/US20120244113A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2004093906A1 (en)	2004-11-04
AU2004231464A1 (en)	2004-11-04
DK1605971T3 (da)	2010-08-16
JP2006523224A (ja)	2006-10-12
EP1605971B1 (en)	2010-05-26
ATE468859T1 (de)	2010-06-15
NZ542652A (en)	2008-04-30
BRPI0408779A (pt)	2006-04-04
CN1764474B (zh)	2011-02-02
MXPA05008526A (es)	2005-10-20
AU2004231464B2 (en)	2010-08-05
US20120244113A1 (en)	2012-09-27
EP1605971A1 (en)	2005-12-21
CA2517010C (en)	2013-09-24
CN1764474A (zh)	2006-04-26
US20070134200A1 (en)	2007-06-14
CA2517010A1 (en)	2004-11-04

Publication	Publication Date	Title
MXPA05008526A (es)	2005-10-20	Metodos y composicion inmunogenica.
Tacket et al.	1999	Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
Ertl et al.	1996	Novel vaccine approaches
Chang et al.	2015	Adjuvant activity of fish type I interferon shown in a virus DNA vaccination model
Konishi et al.	1994	A vipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens
BRPI0414381A (pt)	2006-11-21	composição de adjuvante, composição ou composições imunogênica(s), composição de vacina, processo para a fabricação de uma composição imunogênica, composição ou composições farmacêutica(s), kit, métodos para tratar um paciente que sofre de, ou que é suscetìvel a, um tumor, para incrementar uma resposta imune de um mamìfero a um antìgeno e para suscitar uma resposta imune em m mamìfero contra um estado de doença, usos de uma imidazoquinolina ou derivado da mesma e gm-csf e dos componentes
BR9908267A (pt)	2000-10-24	Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo
DE69835085D1 (de)	2006-08-10	Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
KR20200101416A (ko)	2020-08-27	B형 간염 바이러스(hbv) 백신 및 그 용도
JP6117781B2 (ja)	2017-04-19	交差防御性アレナウイルスワクチンおよびそれらの使用方法
US20190083607A1 (en)	2019-03-21	Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes
Liu et al.	1998	DNA vaccines: mechanisms for generation of immune responses
AR041964A1 (es)	2005-06-01	Vacuna de vhc que comprende un polinucleotido
Kawai et al.	2023	Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses
Lodmell et al.	2001	Post-exposure DNA vaccination protects mice against rabies virus
CO2025015946A2 (es)	2025-11-28	Método para inducir una respuesta inmunitaria
MXPA02005506A (es)	2004-09-10	Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
ATE319833T1 (de)	2006-03-15	Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
WO2022105880A1 (zh)	2022-05-27	融合基因及一种重组新型冠状病毒高效免疫dna疫苗及其构建方法和应用
EP1071377A1 (en)	2001-01-31	Needleless administration of polynucleotide formulations
Ramsay et al.	1997	DNA immunization
Sudarshan et al.	2008	An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax®) in Indian subjects
CY1110205T1 (el)	2015-01-14	Ανοσογονος συνθεση και μεθοδοι
WO2003063786A3 (en)	2004-01-15	Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
CN107812186A (zh)	2018-03-20	C型CpG作为佐剂在HBV预防性以及治疗性疫苗中的应用及其制备方法